Please login to the form below

Not currently logged in
Email:
Password:

Takeda appoints head of vaccines development

John Boslego will succeed Ralf Clemens

edit-Boslego-photo-2Takeda Pharmaceuticals has appointed John Boslego as senior vice president and head of development for its global vaccine business unit, effective from December 1.

He succeeds Ralf Clemens, who has served in the role since the launch of Takeda's vaccine business division in January 2012.

Boslego will be responsible for accelerating global vaccine development activities with a focus on lead development programmes for dengue, norovirus and seasonal influenza. He will report to Rajeev Venkayya, president of Takeda's global vaccine business unit.

Commenting on the appointment, Venkayya said: “John brings a wealth of vaccine development and global health experience to Takeda at an important time.

“He takes the helm of an outstanding development team that was built by Ralf Clemens and I have the utmost confidence in their ability to deliver our exciting pipeline.”

Boslego has work in vaccine clinical research and development for over 40 years and was most recently director of the vaccine development global programme at PATH, where he built a vaccine development organisation and advanced vaccine development against illnesses including rotavirus, polio and meningococcus.

He has also served as executive director of biologics, clinical research at Merck & Co and prior to this, directed the Armed Forces Research Institute of Medical Sciences (AFRIMS) in Bangkok, Thailand.

14th October 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics